CrushSCI.com
78.1Average days
60Median days
30Fastest days
175Longest days
1,0732025 publications

Paper Review Records

All Paper Review Records

11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

82 days

Natural dehydrocostus lactone-based analogues as new structural PDPK1 allosteric activators against HBV

Authors
Hang Sun; Yu-Jing Mao; Dan-Yang Zhu; Rui-Xian Xu; Bi-Cheng Zhang; Ying Sang; Yi-Zhi Liu; Yang Feng; Guotai Yang; Hao Chen; Shao-Xing Dai; Min XuShow moreShow less
Affiliations
Yunnan Key Laboratory of Cross-Border Infectious Disease Control and Prevention and Novel Drug Development (Under Construction), Center for Pharmaceutical Sciences, Faculty of Life Science and Technology, Kunming University of Science and Technology, Chenggong Campus, Kunming, 650500, China; State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, 650500, ChinaShow moreShow less
Source PDF DOI Publisher page
75 days

Exploring the role of conformational restriction in 5-alkyl-6-benzyl-2-{[(methylthio)methyl]thio}pyrimidin-4(3H)-ones: Effects in HIV-1 infected cells and reverse transcriptase enzymes

Authors
Egor Degtyarenko; Gebremedhin Solomon Hailu; Emanuele Fabbrizi; Anastasia Golovina; Andrey Voronkov; Roberta Astolfi; Lidia Giuliani; Andrea Mancini; Maxim B. Nawrozkij; Vladimir Chernyshov; Clarissa Pupillo; Roberto Cirilli; Laura Bavagnoli; Rino Ragno; José A. Esté; Emmanuele Crespan; Francesco Fiorentino; Roman Ivanov; Antonello Mai; Dante RotiliShow moreShow less
Affiliations
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia; Department of Science, Roma Tre University, Rome, 00146, Italy; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, 00185, Italy; Medicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy Ave. 1, Sirius, Krasnodar Region, 354340, Russia; Institute of Biophysics of the Future, Institutsky lane, 9, Building 7, Dolgoprudny, Moscow region, 141701, Russia; Department of Chemistry, Sapienza University of Rome, Pale Aldo Moro 5, Rome, Italy; Centro Nazionale per il Controllo e la Valutazione dei Farmaci, Istituto Superiore di Sanità, Viale Regina Elena 299, Roma, 00161, Italy; Istituto di Genetica Molecolare IGM-CNR, via Abbiategrasso 207, Pavia, 27100, Italy; Universitat Internacional de Catalunya, C/ Josep Trueta s/n., Barcelona, 08195, Spain; Department of Biochemical Sciences, Sapienza University of Rome, Rome, 00185, Italy; Biostructures and Biosystems National Institute (INBB), Rome, 00165, ItalyShow moreShow less
Source PDF DOI Publisher page
99 days

Targeting the myeloid immune checkpoint ILT3 (LILRB4) with small molecules enables reprogramming of suppressive tumor immunity

Authors
Somaya A. Abdel-Rahman; Antonio Monari; Tom Miclot; Florent Barbault; Moustafa T. GabrShow moreShow less
Affiliations
Department of Radiology, Columbia University Irving Medical Center, New York, NY, 10032, USA; Department of Radiology, Weill Cornell Medicine, New York, NY, 10065, USA; Université Paris Cité, CNRS, ITODYS, Paris, F-75013, FranceShow moreShow less
Source PDF DOI Publisher page
30 days

Discovery of a highly selective FLT3-ITD inhibitor with potent antileukemic activity based on 4-(2-fluorophenoxy)pyridine scaffold

Authors
Zhongyuan Wang; Yiwei Zhang; Lin Li; Yunfeng Wang; Dan Yang; Qingmei Song; Qingqing Fu; Dongsheng Zhao; Lei Tang; Weiwei Ouyang; Yue'e Chai; Weike LiaoShow moreShow less
Affiliations
Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, 550002, China; State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550004, China; Department of Oncology, Affiliated Hospital of Guizhou Medical University and Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, 550001, China; Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, 103 Wenhua Road, Shenhe District, Shenyang, 110016, ChinaShow moreShow less
Source PDF DOI Publisher page
40 days

Discovery and characterization of PGC-01: An effective GSDMD-targeting PROTAC

Authors
Qian-qian Wang; Rong-ying Hou; Yi-xuan Shua; Ya-fei Xu; Wen-jing Bian; Wen Xiao; Yu-qing Chen; Bing-yu Zhou; Yue Gao; Li Liu; Yu-hang Wang; Yi-bei Xiao; Cheng JiangShow moreShow less
Affiliations
School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China; Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China; Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaShow moreShow less
Source PDF DOI Publisher page
175 days

In silico identification and biological evaluation of newly synthetic hinokiflavone derivatives as multi-kinase inhibitors with preferential Aurora A activity for ovarian cancer therapy

Authors
Ke Wang; Guan-Yu Chen; Pei‐Yi Chu; Yi-Cheng Pan; Wei-Yu Hsu; Yun-Hao Dai; Yu-Liang Yang; Yeong-Jiunn Jang; Yang-Chang WuShow moreShow less
Affiliations
School of Pharmaceutical Sciences, Jiangsu Provincial University Key Laboratory of Green Biomanufacturing for Pharmaceuticals, Nanjing Tech University, Nanjing, 211816, China; Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, 404327, Taiwan; Master Program of Pharmaceutical Manufacture, College of Pharmacy, China Medical University, Taichung, Taiwan; Agricultural Biotechnology Research Center, Academia Sinica, Taipei, 11529, Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, 404333, Taiwan; Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, TaiwanShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY take to review a manuscript?

As of 2026-11-19, CrushSCI has 11 complete review records for EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. The fastest paper went from submission to acceptance in 30 days (Discovery of a highly selective FLT3-ITD inhibitor with potent antileukemic activity based on 4-(2-fluorophenoxy)pyridine scaffold, received 2026-07-28, accepted 2026-08-27); the slowest took 175 days. The average is 78.1 days and the median is 60 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.